FDA authorizes second booster of Pfizer/BioNTech COVID shot
U.S. regulators authorized a second booster dose of Pfizer Inc (PFE.N) and BioNTech SE's (22UAy.DE) COVID-19 vaccine for people 50 and older due to concerns about waning immunity in the age group, the drugmakers said on Tuesday. The U.S. Food and Drug Administration...
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
InnoCare Pharma announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Company's third innovative drug...
Google Tests Catching Heart, Eye Issues From Smartphone Sensors
Google announced on Thursday its latest plans for using smartphones to monitor health, saying it would test whether capturing heart sounds and eyeball images could help people identify issues from home. The company, a unit of Alphabet Inc, is investigating whether the...
How Innovative AI and Digital Health Data are Making Strides in Patient-Focused Care
What if AI could use digital health data to correctly identify the early signs of a serious health issue that is extremely hard to diagnose, yet widespread in hospital settings? In one recent example of healthcare innovation, a cutting-edge AI system that analyzes...
Pfizer Notches Breakthrough Status in Race to an RSV Vaccine
Pfizer has announced Thursday that it received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its vaccine candidate PF-06928316 (RSVpreF), intended to prevent infections caused by a respiratory syncytial virus (RSV). The respiratory...
With Robust Results, Moderna to Request Vaccine EUA for Kids Under 6
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age. The data showed a “robust neutralizing antibody response” in both cohorts. The doses were...
Takeda’s Parathyroid Hormone Injection Delayed Indefinitely
Takeda faces yet another setback by the U.S. Food and Drug Administration for its parathyroid hormone, natpara. Natpara is intended to help patients navigate low blood calcium due to hypoparathyroidism. In Sept. 2019, Takeda issued a U.S. recall of all natpara for...
A New Day in Cancer Treatment: FDA Approves BMS’s Opdualag
Bristol Myers Squibb (BMS) achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of patients 12 and older with unresctable or metastatic melanoma. The decision is based on the...
Moderna and Pfizer are seeking FDA approval for second COVID-19 boosters.
Moderna formally requested the FDA grant emergency authorization for a second booster shot of its COVID-19 vaccine for all adults over 18 who have received approved vaccines. Earlier this week, Pfizer and its partner BioNTech also requested authorization for a second...
COVID-19 Update: The Diabetes Connection, WHO Concerned about BA.2
Viral infections can have a broad range of side effects, such as myocarditis, and COVID-19 is no different. There is evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, an autoimmune disease most commonly...
FDA approves Four Cancer Clinical Trials
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment, including Sonnet BioTherapeutics and Adagene. Sonnet BioTherapeutics evolved into a clinical biopharmaceutical...
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Arrowhead Pharmaceuticals, Inc. has announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for...
CDE Approves the Inclusion of Hexvix® in the Clinical Real-world Evidence Pilot Study
Asieris Pharmaceuticals, in accordance with advice from the National Medical products Administration Center for Drug Evaluation (CDE), has approved the inclusion of Asieris’s drug Hexvic®, a drug for the diagnosis of bladder cancer, in the clinical real-world world...
Supporting Patient Centricity in Clinical Trials Through Advanced NLP AI
As anyone working within the clinical trial space will know, a crucial phase of the early trial process is pre-screening patients to match to a specific clinical trial and the importance of patient centricity throughout this process. The pre-screening process has...
Hoth Therapeutics: Orphan Drug Designation for HT-KIT
Hoth Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HT-KIT to treat mastocytosis. Mastocytosis is a rare condition caused by an abnormal accumulation and activation of mast cells in the skin, bone...
C4 Therapeutics: Orphan Drug Designation for CFT8634
C4 Therapeutics (C4T) has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 to treat soft tissue sarcoma. Soft tissue sarcoma is a rare type of cancer that begins in the tissues that connect, support, and...
7 Hills Pharma: FDA Fast Track Designation for 7HP349
7 Hills Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead clinical-stage immunostimulant 7HP349, combined with a CTLA-4 inhibitor, to treat unresectable or metastatic malignant melanoma if...
Genmab: Orphan Drug Designation for Epcoritamab
Genmab A/S has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine epcoritamab (DuoBody®-CD3xCD20) to treat follicular lymphoma (FL). FL is usually a slow-growing or indolent form of...
FDA sNDA: Servier’s TIBSOVO® to Treat Acute Myeloid Leukemia
Servier has announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for TIBSOVO® (ivosidenib tablets) in combination with azacitidine to potentially treat patients with previously untreated...
Tonix Pharmaceuticals: Orphan Drug Designation for TNX-2900
Tonix Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for TNX-2900 (intranasal potentiated oxytocin) to treat Prader-Willi syndrome. Prader-Willi syndrome is a rare genetic disorder that causes...